Impact News +++ Accenture Plc Bottom Line Drops In Q1 (AFX) +++ ACCENTURE Aktie -4,18%

AMNEAL Aktie

>AMNEAL Aktienkurs

10.6 EUR (Tradegate)

Ask: 10.8 EUR / 400 Stück

Bid: 10.4 EUR / 400 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AMNEAL Aktie über LYNX handeln

Intraday

1 Jahr

>AMNEAL Performance

1 Woche: 0%

1 Monat: +4,0%

3 Monate: +27,6%

6 Monate: +49,6%

1 Jahr: +35,1%

laufendes Jahr: +40,5%

>AMNEAL Aktie

Name:

AMNEAL PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US03168L1052 / A2JLMD

Symbol/ Ticker:

2DT (Frankfurt) / AMRX (NASDAQ)

Kürzel:

FRA:2DT, ETR:2DT, 2DT:GR, NASDAQ:AMRX

Index:

Webseite:

https://www.amneal.com/

Profil:

Amneal Pharmaceuticals Inc. is a renowned entity i..
>Volltext..

Marktkapitalisierung:

3261.09 Mio. EUR

Unternehmenswert:

5408.64 Mio. EUR

Umsatz:

2501.74 Mio. EUR

EBITDA:

515.52 Mio. EUR

Nettogewinn:

5.03 Mio. EUR

Gewinn je Aktie:

0.02 EUR

Schulden:

2289.3 Mio. EUR

Liquide Mittel:

201.14 Mio. EUR

Operativer Cashflow:

279.32 Mio. EUR

Bargeldquote:

0.27

Umsatzwachstum:

3.89%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 586.000 USD.

Suchwörter:

AMNEAL

Letzte Datenerhebung:

18.12.25

>AMNEAL Kennzahlen

Aktien/ Unternehmen:

Aktien: 314.36 Mio. St.

Frei handelbar: 49.87%

Leerverk. Aktien: 1.95%

Rückkaufquote: -0.04%

Mitarbeiter: 8300

Umsatz/Mitarb.: 0.29 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 13.97%

Bewertung:

KGV: 859.42

KGV lG: 15.3

KUV: 1.34

KBV: -

PEG-Ratio: -

EV/EBITDA: 10.49

Rentabilität:

Bruttomarge: 36.76%

Gewinnmarge: 0.2%

Operative Marge: 12.41%

Managementeffizenz:

Gesamtkaprendite: 0.17%

Eigenkaprendite: -

>AMNEAL Peer Group

Es sind 599 Aktien bekannt.

>AMNEAL Chart & Kurs - NASDAQ

>AMNEAL News

09.12.25 - 22:25	Amneal-Aktie steigt nach FDA-Zulassung für Epinephrin-Injektion (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.12.25 - 22:06

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals (GlobeNewswire EN)

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care....

05.12.25 - 14:03	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson′s Disease (GlobeNewswire EN)
	BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson's Study Group (PSG) Annual Meeting....

02.12.25 - 14:03	Amneal to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:...

02.12.25 - 05:12	Amneal Pharma Receives FDA Approval For Cyclosporine Ophthalmic Emulsion 0.05% (AFX)
	WASHINGTON (dpa-AFX) - Amneal Pharmaceuticals Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved the company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preserv......

01.12.25 - 22:03

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% (GlobeNewswire EN)

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company....

29.11.25 - 00:24	Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? (Fool)
	The pharmaceutical company has experienced sales growth over the past five years....

21.11.25 - 19:00	Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs (Fool)
	One executive's option-linked sale may look large on paper, but the broader context tells a more nuanced story....

20.11.25 - 02:02	Insiderhandel: Aufsichtsrat verkauft Aktien von Amneal Pharmaceuticals im Wert von 586000 USD (Insiderkauf)
	Nark, Ted C. - Aufsichtsrat - Tag der Transaktion: 2025-11-17...

15.11.25 - 02:01	Insiderhandel: Executive Vice President verkauft Aktien von Amneal Pharmaceuticals im Wert von 1571724 USD (Insiderkauf)
	Shah, Nikita - Vorstand - Tag der Transaktion: 2025-11-12...

13.11.25 - 22:03	Amneal Receives U.S. FDA Approval for Iohexol Injection (GlobeNewswire EN)
	First-to-market complex injectable with expected launch in Q1 2026 First-to-market complex injectable with expected launch in Q1 2026...

07.11.25 - 18:54	S&P Global hebt Ausblick für Amneal Pharmaceuticals auf "Positiv" an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 18:00	Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 15:45	Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
	While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

30.10.25 - 13:30	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
	Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

30.10.25 - 11:06	Amneal Pharmaceuticals Non-GAAP EPS of $0.17 beats by $0.03, revenue of $785M beats by $11.19M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 11:03	Amneal Reports Third Quarter 2025 Financial Results (GlobeNewswire EN)
	‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒...

29.10.25 - 16:06	Amneal Pharmaceuticals Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 13:03

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches (GlobeNewswire EN)

BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 The Brekiya autoinjector is now available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy....

23.10.25 - 17:30	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram